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Purpose: To investigate a possible association between Fuchs’ endothelial corneal dystrophy 
(FECD) and hearing disability.
Methods: A cross-sectional observational study was performed at the University Medical 
  Center Utrecht. Cases and controls were patients who were treated by a cornea specialist between 
2004 and 2008. FECD patients had either already undergone or were planned for a keratoplasty 
procedure. All controls were patients treated for cataract without any corneal pathology. Cases 
and controls were matched by age group and gender. A structured telephone interview combined 
with a validated self-perceived hearing function test (the Hearing Handicap Inventory for the 
Elderly, screening version; HHIE-S) was used for data collection.
Results: Hearing disability was reported in 33 patients (45.8%) in the FECD-group (n = 72, 
average age: 73 years) versus 50 patients (34.7%) in the control group (n = 144, average age: 
73 years). Hearing disability was significantly associated with FECD after adjustment for age, 
noise exposure, and diabetes mellitus (odds ratio 1.97 95% confidence interval 1.04–3.75).
Conclusion: This case–control study reports a significant association between FECD and 
hearing disability. The causal relation was not evaluated in this study, though mutations in the 
SLC4A11 gene could have played an important role. This gene encodes for an ion transporter, 
which has been found in the cornea and inner ear. With the lack of examination with a pure 
tone or speech audiometry in this study, further studies need to be performed in order to sup-
port the association and should include a complete ENT examination with audiometry and 
genetic research.
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Introduction
Fuchs’ endothelial corneal dystrophy (FECD) is a progressive degeneration of the 
corneal endothelium that can lead to corneal opacification, resulting in the need 
for a keratoplasty procedure in the final stage. FECD is the most common posterior 
  corneal dystrophy affecting elderly patients, with a preference for women.1–3 The 
exact incidence of FECD is not known. The most common first sign of the disease 
is the formation of guttate excrescences. The cornea guttata are seen quite often and 
increase with age. No consistent figures are available. In a recent population-based 
study in Japan, for example, the prevalence of cornea guttata was 4.1% among 
residents of $40 years4, whereas in the Reykjavik Eye Study a prevalence of 9.2%   
was found in participants of $55 years.5
The posterior corneal dystrophies are all thought to represent defects of neural crest 
terminal differentiation.1–3,6 In FECD, this results in a dysfunction of the endothelium, Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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a monolayer of cells which normally maintains corneal   clarity 
by keeping the stroma in a state of relative dehydration 
and providing coverage of the posterior corneal surface.2,7 
Although FECD is a common disorder, described by Ernst 
Fuchs in 1910,6 the knowledge of etiology and disease 
progression in this age-related endothelial dystrophy is still 
limited. The disorder is usually sporadic, but familial highly 
penetrant forms with an autosomal dominant inheritance 
pattern have been described.3,8–10
At our institution (University Medical Center Utrecht, 
UMCU), a high frequency of hearing impairment among 
FECD patients was subjectively observed. Due to the limited 
knowledge of the etiology of FECD, co-pathology in other 
organs could have remained unrecognized.
The combination of an endothelial dystrophy and 
  sensorineural hearing loss is not a rare phenomenon. Among 
the posterior corneal dystrophies, Harboyan syndrome 
is known as a corneal dystrophy and perceptive deafness 
(CDPD), usually developing during the second decade of 
life.11,12 A recent study showed that mutations in the SLC4A11 
gene will result in endothelial dystrophy and sensorineural 
hearing loss. This mutation has been found in Harboyan 
syndrome as well as FECD and raised the question whether 
the subjectively observed high frequency of hearing disability 
among FECD patients is not merely a coincidence.
This case–control study was performed to examine the 
hypothesis of whether FECD and hearing disability are 
associated.
Materials and methods
Study design and study population
A case–control study, cross-sectional observational, was con-
ducted at UMCU, The Netherlands, following the tenets of the 
Helsinki declaration of 1975 and approved by the accredited 
Medical Review Ethics Committee of the UMCU. Initially, all 
patients who were examined by the cornea specialist and diag-
nosed with FECD between 2004 and 2008, were included in 
the study if they had either already undergone or were planned 
for a keratoplasty procedure. For each case, 2 controls were 
randomly selected from cataract surgery patients, operated   
in the same time period and with frequency-matching on 
5-year age group and gender. Patients with cognitive disor-
ders or who did not consent to participation were excluded, 
as were controls with corneal pathology.
Data collection
All eligible participants (both FECD and controls) received a 
letter, consisting of an information form and the questionnaire 
which was used in this study. One week later, participants 
were contacted by telephone and were interviewed. This time 
interval was chosen to provide participants sufficient time 
to study the questionnaire, and to minimize the chance that 
questions were unclear during the telephone interview. All 
interviews were performed by one of the authors (MS) who 
was not blinded for case-control status. Five attempts without 
establishing telephone contact resulted in an exclusion from 
the study. Relevant information on ocular pathology was 
obtained from the patient record.
Study instrument
The questionnaire was conducted as a telephone interview, 
enabling a large cohort group of patients and controls to be 
reached. The main topic of the questionnaire was the vali-
dated self-perceived hearing function test: the Hearing Handi-
cap Inventory for the Elderly screening version (HHIE-S). 
An additional topic in the questionnaire were the factors that 
could have had an influence on the patient’s hearing function 
(  possible risk factors): noise exposure (during leisure and 
work), ear- and hearing-related medical history (wearing 
a hearing aid, prior ear surgery and/or pathology), diabetes 
mellitus,13 myotonic dystrophy, ototoxic medication, smoking 
(positive if previously or presently smoking), and level of 
education (primary, secondary, and higher education).
The HHIE-S version14,15 is a validated 10-item question-
naire and scores each answer. The total scores range from 
0 (no handicap) to 40 (maximum handicap). Different studies 
provided by ear/nose/throat (ENT) physicians found that this 
test is able to accurately diagnose hearing disability with a 
scores of $10 (sensitivity 0.58–0.74, specificity 0.68–0.85) 
compared with pure tone audiometry.15–19 An HHIE-S score 
of $10 was considered a hearing disability in this study.
Statistical analysis
Statistical analysis was performed by SPSS, version 15.0 
for Windows. The discrete variables were measured with 
Chi-square test and Fischer’s exact test. The independent-
samples t-test was used for continuous nominal distributed 
variables.
Using binary logistic regression, the association between 
FECD and hearing disability was corrected for confound-
ers that changed the odds ratio (OR) by .5%. A P value 
of ,0.05 was considered statistically significant.
Results
Based on patients’ records, in total 87 patients with FECD 
were eligible to be enrolled in our study. Five patients had Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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passed away and 72 of the 82 invited patients agreed to 
participate. Of the non-participants, 3 were unreachable by 
telephone and 7 patients were unwilling to participate. For 
the included 72 FECD patients, 180 matched controls were 
found based on patient records. Of the 180 invited controls 
144 agreed to participate. Of the non-participants, 20 were 
unreachable by telephone and 16 patients were unwilling to 
participate. The main reason for declining participation for 
both groups was overall severe illness and living abroad. All 
participants (FECD and controls) completed their interview 
and there were no difficulties in obtaining the answers.
Overall, 216 participants (72 FECD patients and 
144 controls) were enrolled in this case–control study, 
patient age ranging between 53 and 91 years (mean 73.4 
years ± 8.9) and a male:female ratio of 1:1. Table 1 shows 
the baseline characteristics, with no significant differences 
between the FECD and the control group. Possible risk fac-
tors for hearing disability are shown in Table 2, with age as 
a significant risk factor and noise exposure almost reaching 
significance. None of the participants were diagnosed with 
myotonic dystrophy. Chi-square and t-tests were used for 
P-value calculations in Tables 1 and 2. Overall, 83 participants 
reported hearing   disability in accordance with the HHIE-S. 
A higher   percentage in the FECD group reported hearing dis-
ability (45.8%, 33 patients) compared with the control group 
(34.7%, 50 controls) (OR 1.59; 95% confidence interval [CI] 
0.89–2.83) (Table 3). This is in accordance with the P value 
of 0.14, reflecting the crude association between FECD and 
hearing disability (Table 2). Therefore we performed binary 
logistic regression to show an association between FECD 
and hearing disability after correction for confounders. Age, 
noise   exposure, and diabetes mellitus changed the OR by more 
Table 2 Overview of the risk factors
Risk factor With HD  
no. (%)
Without HD  
no. (%)
P value
All subjects n = 216 83 (38.4) 133 (61.6)
FeCD 33 (39.8) 39 (29.3) 0.14
Age Mean, SD 77.1  ±7.8 71.1  ±8.9 0.00
gender Male 40 (48.2) 65 (48.9) 1.0
noise exposure 16 (19.3) 13 (9.8) 0.06
Ototoxic medication 1 (1.2) 0 (0) 0.38
ear historya 12 (14.5) 10 (7.5) 0.11
Diabetes mellitus 12 (14.5) 13 (9.8) 0.38
Smoking 51 (61.4) 72 (54.1) 0.32
Level of education
Primary 26 (31.7) 27 (20.5)
Middle 27 (32.9) 48 (36.4) 0.17
high 29 (35.4) 57 (43.2)
Note: aear and hearing-related medical history.
Abbreviations: FeCD, Fuchs’ endothelial corneal dystrophy; hD, hearing disability; 
SD, standard deviation.
Table 1 Baseline characteristics of the study population
Characteristic FECD  
no. (%)
Controls  
no. (%)
P value
All subjects 72 144  
Agea Mean, SD 73.4  ±9.2 73.4  ±8.9 0.97
gendera Male 35 (48.6) 70 (48.6) 1.0
noise exposure 7 (9.7) 22 (15.3) 0.30
Ototoxic medication 0 (0) 1 (0.7) 1.0
ear historyb 6 (8.3) 16 (11.1) 0.64
Diabetes mellitus 5 (6.9) 20 (13.9) 0.18
Smoking 41 (56.9) 82 (56.9) 1.0
Level of education
Primary 20 (27.8) 33 (23.2)
Middle 24 (33.3) 51 (35.9) 0.80
high 28 (38.9) 58 (40.8)
Notes: aMatching variables; bear and hearing-related medical history.
Abbreviations: FeCD, Fuchs’ endothelial corneal dystrophy; hD, hearing disability; 
SD, standard deviation.
than 5% and were included in the binary logistic regression to 
describe the unbiased association between FECD and hear-
ing disability. After adjustment for age, noise exposure, and 
diabetes mellitus, a significant association was found between 
FECD and hearing disability (OR 1.97; 95% CI 1.04–3.75).
Discussion
This case–control study reported a significant association 
between FECD and hearing disability with an OR of 1.97 
(95% CI 1.04–3.75) after correction for confounders. In 
the FECD group, 45.8% reported a hearing disability in 
accordance with the HHIE-S; this was 34.7% in the control 
group.
The first signs of FECD become evident in the fourth 
or fifth decade of life, but often do not produce symptoms 
until a decade or more later. The mean age of the   participants 
(73.4 years) in this study is comparable with that of the gen-
eral patient population with FECD who are under (short- or 
long-term) treatment of a cornea specialist. Patients and 
medical professionals often consider hearing loss as an 
age-related, physiological change. Hence, an association 
between FECD and hearing disability in this elderly patient 
group may have been overlooked in clinical practice by 
ophthalmologists.
Congenital corneal endothelial dystrophy (CHED2) 
and Harboyan syndrome (CDPD), both syndromes with 
sensorineural hearing loss, are associated with mutations in 
the SLC4A11 gene, whereas heterozygous mutations in the 
SLC4A11 gene are found in the late-onset FECD.10,12,20–22 The 
SLC4A11 gene encodes for an ion-transporter and is essential 
for cell growth, proliferation and differentiation, as early as 
during the embryonic stage. The ion transporter SLC4A11 Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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can mediate the flux of Na+ and OH− into cells and Na+/borate 
co-transport in the presence of borate.21–23
The association between endothelial dystrophy and hear-
ing impairment has recently been shown in an experimental 
model, where mutations in the SLC4A11 gene resulted in 
deafness, endothelial dystrophy, and polyuria.20 In this mouse 
model SLC4A11 is expressed in the endothelium of the cor-
nea, in the thin descending part of Henle’s loop in the kidney, 
and in fibrocytes of the inner ear. The role of SLC4A11 in 
the mice was studied by inactivation of the gene by targeted 
mutagenesis, which resulted in corneal dystrophy, deafness, 
and polyuria.20 The cornea of the knock-out mice showed a 
thickening of several layers, an increased sodium concen-
tration in endothelial cells, and an accumulation of sodium 
chloride in the corneal stroma. Because the SLC4A11 can act 
as a sodium channel, this suggests that the loss of SLC4A11 
results in a disturbance of ion gradients and will disrupt the 
intricate balance of the flux of fluids. The inner ear showed 
severe disruptions in the typical morphology of fibrocytes 
with numerous intracellular vacuolations and extracellular 
edemas, also indicating a disturbance of the osmotic balance 
of these cells. A strongly reduced endocochlear potential was 
measured in the SLC4A11 knock-out mice. The reduction of 
the endocochlear potential disables outer hair cells to amplify 
auditory signal.
The findings of Gröger et al combined with reports of 
heterozygous mutations of SLC4A11 in the late-onset FECD, 
could support the association between hearing disability 
and FECD found in this study. With the use of a validated 
test, this study measured the frequency of hearing disability 
among participants and did not investigate the cause (inner-, 
middle- or external-ear) and type (conductive or perceptive) 
of hearing impairment, while the hypothesis of the associa-
tion is based on perceptive hearing loss, ie, sensorineural 
hearing loss as a result of a malfunction of the sensory 
cells and the nerve fibers in the inner ear. Further research 
should be performed with at least routine ENT examination 
and pure tone as well as speech audiometry. To support the 
above-mentioned hypothesis, genetic testing in these indi-
viduals could shed light on the association between FECD 
and hearing disability.
Potential limitations of our analysis include the self-
perceived hearing function used, although this is a validated 
test. There was no additional audiometric proof of the hearing 
disability in the participants who reported this according to 
the questionnaire. However, the HHIE-S is a widely used, 
well-validated questionnaire and a threshold of $10, as used 
in this study, maximizes the test accuracy. With this cut-off 
score, the sensitivity ranges from 0.58 to 0.74, and specificity 
from 0.68 to 0.85.14–19,24 The recall-based assessments of all 
hearing disability-related information could also lead to mea-
surement errors, although these had equal chances of occur-
ring in both groups. In an attempt to minimize inter-observer 
bias, all interviews were performed by only one interviewer. 
In addition, the interviews were performed unblinded, which 
could have influenced our results. Hearing impairment was 
reported more frequently in the FECD group than in the 
control group, but did not reach significance without correct-
ing for confounders. A possible explanation is the relatively 
small study population, which can be confirmed by the low 
significance rate of risk factors in Table 2 and the almost 
equal gender ratio. In addition, this study did not perform 
genetic testing. In accordance with the literature,12 only some 
of our FECD participants could have had the mutation in the 
SLC4A11 gene. Based on the above-mentioned hypothesis, 
only the participants with this mutation could have been 
responsible for the association with hearing disability; this 
remains to be investigated.
In conclusion, this study reported a strong association 
between FECD and hearing disability. It suggests that hear-
ing disability could be a co-pathology in FECD, though this 
study did not investigate the causal relationship between 
FECD and hearing disability. Further studies including ENT 
examination with pure tone as well as speech audiometry in 
combination with genetic research to evaluate the presence 
of the SCL4A11 mutation, need to be performed to support 
our hypothesis of an association between (a subgroup of) 
FECD and hearing disability.
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Table 3 Crude and adjusted associations between hearing impairment and FeCD
Variable
 
No. of subjects (%) Total no. Unadjusted odds ratio 
(95% CI)
Adjusted odds ratio 
(95% CI) FECD Controls
hD yes 33 (45.8) 50 (34.7) 83 1.59 (0.89–2.83) 1.97 (1.04–3.75)
hD no 39 (54.2) 94 (65.3) 133
Notes: aAdjusted for age, noise exposure, and diabetes mellitus.
Abbreviations: FECD, Fuchs’ endothelial corneal dystrophy; HD, hearing disability; CI, confidence interval.Clinical Ophthalmology
Publish your work in this journal
Submit your manuscript here: http://www.dovepress.com/clinical-ophthalmology-journal
Clinical Ophthalmology is an international, peer-reviewed journal 
covering all subspecialties within ophthalmology. Key topics include: 
Optometry; Visual science; Pharmacology and drug therapy in eye 
diseases; Basic Sciences; Primary and Secondary eye care; Patient 
Safety and Quality of Care Improvements. This journal is indexed on 
PubMed Central and CAS, and is the official journal of The Society of 
Clinical Ophthalmology (SCO). The manuscript management system 
is completely online and includes a very quick and fair peer-review 
system, which is all easy to use. Visit http://www.dovepress.com/ 
testimonials.php to read real quotes from published authors.
Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
Dovepress
1301
hearing disability in Fuchs’ dystrophy
Disclosure
The authors disclose no conflicts of interest or receipt of 
  funding for this study.
References
  1.  Bahn CF, Falls HF, Varley GA, Meyer RF, Edelhauser HF, Bourne WM. 
Classification of corneal endothelial disorders based on neural crest 
origin. Ophthalmology. 1984;91:558–563.
  2.  Bergmanson JP, Sheldon TM, Goosey JD. Fuchs’ endothelial 
  dystrophy: a fresh look at an aging disease. Ophthalmic Physiol Opt. 
1999;19:210–222.
  3.  Weiss JS, Moller HU, Lisch W, et al. The IC3D classification of the 
corneal dystrophies. Cornea. 2008;27 Suppl 2:S1–S83.
  4.  Higa A, Sakai H, Sawaguchi S, et al. Prevalence of and risk factors for 
cornea guttata in a population-based study in a southwestern island of 
Japan: the Kumejima study. Arch.Ophthalmol. 2011;129:332–336.
  5.  Zoega GM, Fujisawa A, Sasaki H, et al. Prevalence and risk   factors 
for cornea guttata in the Reykjavik Eye Study. Ophthalmology. 
2006;113:565–569.
  6.  Fuchs EE. Dystrophia epithelialis corneae. Albrecht Von Graefes Arch 
Klin Exp Ophthalmol. 1910;76:478–508.
  7.  Slettedal  JK,  Lyberg T,  Roger  M,  Beraki  K,  Ramstad  H, 
Nicolaissen B. Regeneration with proliferation of the endothelium of 
cultured human donor corneas with extended postmortem time. Cornea. 
2008;27:212–219.
  8.  Gottsch JD, Sundin OH, Liu SH, et al. Inheritance of a novel COL8A2 
mutation defines a distinct early-onset subtype of fuchs corneal dystro-
phy. Invest Ophthalmol Vis Sci. 2005;46:1934–1939.
  9.  Rosenblum P, Stark WJ, Maumenee IH, Hirst LW, Maumenee AE. 
Hereditary Fuchs’ Dystrophy. Am J Ophthalmol. 1980;90:455–462.
  10.  Vithana EN, Morgan P, Sundaresan P, et al. Mutations in sodium-
borate cotransporter SLC4A11 cause recessive congenital hereditary 
endothelial dystrophy (CHED2). Nat Genet. 2006;38:755–757.
  11.  Abramowicz MJ, Buquerque-Silva J, Zanen A. Corneal dystrophy and 
perceptive deafness (Harboyan syndrome): CDPD1 maps to 20p13.   
J Med Genet. 2002;39:110–112.
  12.  Vithana EN, Morgan PE, Ramprasad V, et al. SLC4A11 muta-
tions in Fuchs endothelial corneal dystrophy. Hum Mol Genet. 
2008;17:656–666.
  13.  Bainbridge KE, Hoffman HJ, Cowie CC. Diabetes and hearing impair-
ment in the United States: audiometric evidence from the National 
Health and Nutrition Examination Survey, 1999 to 2004. Ann Intern 
Med. 2008;149:1–10.
  14.  Ventry IM, Weinstein BE. Identification of elderly people with hearing 
problems. ASHA. 1983;25:37–42.
  15.  Weinstein BE. Validity of a screening protocol for identifying elderly 
people with hearing problems. ASHA. 1986;28:41–45.
  16.  Lichtenstein MJ, Bess FH, Logan SA. Validation of screening tools 
for identifying hearing-impaired elderly in primary care. JAMA. 
1988;259:2875–2878.
  17.  Lichtenstein MJ, Bess FH, Logan SA. Diagnostic performance of the 
hearing handicap inventory for the elderly (screening version) against 
differing definitions of hearing loss. Ear Hear. 1988;9:208–211.
  18.  McBride WS, Mulrow CD, Aguilar C, Tuley MR. Methods for screening 
for hearing loss in older adults. Am J Med Sci. 1994;307:40–42.
  19.  Sindhusake D, Mitchell P, Smith W, et al. Validation of self-reported 
hearing loss. The Blue Mountains Hearing Study. Int J Epidemiol. 
2001;30:1371–1378.
  20.  Romero MF, Fulton CM, Boron WF. The SLC4 family of HCO 3 – 
transporters. Pflugers Arch. 2004;447:495–509.
  21.  Desir J, Moya G, Reish O, et al. Borate transporter SLC4 A11 mutations 
cause both Harboyan syndrome and non-syndromic corneal endothelial 
dystrophy. J Med Genet. 2007;44:322–326.
  22.  Park M, Li Q, Shcheynikov N, Muallem S, Zeng W. Borate transport 
and cell growth and proliferation. Not only in plants. Cell Cycle. 
2005;4:24–26.
  23.  Groger N, Frohlich H, Maier H, et al. SLC4A11 prevents osmotic imbal-
ance leading to corneal endothelial dystrophy, deafness, and polyuria. 
J Biol Chem. 2010;285:14467–14474.
  24.  Mulrow CD, Tuley MR, Aguilar C. Discriminating and responsiveness 
abilities of two hearing handicap scales. Ear Hear. 1990;11:176–180.